Midatech Pharma jumps as dosage study of brain tumor treatment meets main goal

Biodexa Pharmaceuticals

19/10/2020 12:26

** UK drug developer's U.S.-listed shares  MTP.O  surge 37%
to near 3-mth high of $2.74 premarket 
    ** Co says early-stage study of its drug candidate, MTX110, 
met the main goal of determining the dosage regimen to be used
in a proposed Phase 2 trial  urn:newsml:reuters.com:*:nACSx8S7la
    ** Drug is to treat patients with Diffuse Intrinsic Pontine
Glioma, a type of brain tumor
    ** Data from the study supports a dose of between 60
micromolar and 90 micromolar of MTX110 over the course of 12
infusions - MTP
    ** Up to Friday's close, stock down ~42% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))